This study aimed to elucidate the cytoprotective effects of XOR inhibition on GEC injury and the precise mechanism of AMPK activation associated with the purine salvage pathway by XOR inhibition using an in vitro model of DKD involving high glucose (HG)-treated human GECs. Here, PRKAA2 is linked to diabetic kidney disease.